 HOUSTON, Jan. 28, 2021 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration FDA has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 12 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. 